TrialCurrent Alzheimer research2017
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial.
Boris Decourt et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
28 papers cite it
this paperpooled itcites it